Business Context and Reporting Period
Company: InnovAge Holding Corp. (INNV)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: InnovAge is the largest Program of All-Inclusive Care for the Elderly (PACE) provider in the U.S. by participant count. The company operates a fully capitated, value-based care model for frail, dual-eligible seniors (Medicare and Medicaid). As of June 30, 2024, InnovAge served approximately 7,020 participants across 20 centers in six states (Colorado, California, Florida, New Mexico, Pennsylvania, and Virginia). The company manages its business as a single reportable segment: PACE.
Key Financial Metrics
| Metric (in thousands, except per share) | Year Ended June 30, 2024 | Year Ended June 30, 2023 |
|---|---|---|
| Total Revenues | $763,855 | $688,087 |
| Net Loss | $(23,221) | $(43,552) |
| Net Loss Attributable to InnovAge | $(21,338) | $(40,673) |
| Operating Loss | $(23,180) | $(49,395) |
| Adjusted EBITDA (Non-GAAP) | $16,474 | $(3,425) |
| Center-Level Contribution Margin (Non-GAAP) | $132,064 | $101,288 |
| Cash and Cash Equivalents (End of Period) | $56,946 | $127,249 |
| Total Debt (Principal) | $65,989 | $69,784 |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.30) |
Liquidity: The company had $56.9 million in cash and cash equivalents as of June 30, 2024, a decrease of $70.3 million from the prior year, primarily due to the Concerto acquisition and working capital changes. The company maintains a $100 million Revolving Credit Facility with $96.1 million available capacity.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.0% to $763.9 million, driven by a 4.5% increase in member months (due to the release of enrollment sanctions in California and Colorado) and a 6.3% increase in capitation rates.
- Profitability Improvement: Net loss narrowed significantly by 47% year-over-year. Adjusted EBITDA turned positive, increasing from a loss of $3.4 million to a profit of $16.5 million.
- Expense Trends: Total operating expenses increased 6.7% to $787.0 million. External provider costs rose 7.6% due to higher member months and increased cost per participant (driven by assisted living utilization and wage inflation). Corporate, general, and administrative expenses decreased 3.7% due to reduced legal, insurance, and consulting costs.
- Acquisitions: In December 2023, the company acquired two California-based PACE programs (ConcertoCare) for $23.9 million, adding one operating center in Los Angeles and a planned center in Bakersfield.
- Expansion: Opened two de novo centers in Florida (Tampa and Orlando) during the fiscal year.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management expects to focus on increasing enrollment and capacity utilization at existing centers in fiscal 2025. The company plans to continue investing in clinical value initiatives to manage cost trends and expand via de novo centers and tuck-in acquisitions. However, the opening of planned de novo centers in Downey and Bakersfield, California, is currently precluded due to the suspension of state attestations by the California Department of Health Care Services (DHCS) following audits.
Key Risks:
- Regulatory and Audit Risks: The company is subject to ongoing federal and state audits (including a medical review of the San Bernardino center). Adverse findings could lead to enrollment sanctions, repayment obligations, or fines. The suspension of attestations for California de novo centers remains a critical operational risk.
- Legal Proceedings: The company is subject to civil investigative demands from the DOJ and the Colorado Attorney General under False Claims Acts regarding billing and patient services. Additionally, there are pending stockholder lawsuits alleging securities violations and breach of fiduciary duty.
- Cost of Care: The company assumes 100% of the financial risk for participant care. Rising labor costs, inflation, and increased acuity of the participant population could cause medical expenses to exceed capitation payments.
- Concentration Risk: Revenue is heavily dependent on government payors (Medicare and Medicaid), with Colorado, California, and Virginia accounting for approximately 84.3% of capitation revenue in 2024.
Unusual Items: The company recognized a $2.8 million gain on cost and equity method investments in 2024, primarily from the dissolution of a senior housing partnership (PWD), partially offset by a $2.0 million impairment of an investment in Jetdoc. A $1.3 million settlement for a wage and hour class action lawsuit was paid in June 2024.
Investor Verification Checklist
- Regulatory Status: Verify the current status of the DHCS audit and the timeline for reinstating state attestations required to open the Downey and Bakersfield, California centers.
- Legal Exposure: Monitor developments in the DOJ and Colorado False Claims Act investigations and the pending securities class action lawsuit.
- Cost Management: Assess the effectiveness of clinical value initiatives in controlling the rising cost of care, particularly regarding external provider costs and labor inflation.
- Liquidity Position: Review the cash burn rate and the company's ability to fund growth and debt service given the significant decrease in cash balances ($70.3 million drop) during the fiscal year.
- Enrollment Trends: Confirm that the release of sanctions in California and Colorado has resulted in sustained enrollment growth and that disenrollment rates remain manageable despite competitive pressures.